Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Asthma and COPD Drugs Market size was over USD 26.1 billion in 2024 and is estimated to reach USD 45.6 billion by the end of 2037, expanding at a CAGR of 5.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of asthma and COPD drugs is assessed at USD 27.4 billion.
The exceeding patient population of asthma and Chronic Obstructive Pulmonary Disease (COPD) is creating a surge for therapeutics, offering instant relief and effective disease management. In this regard, the WHO reported that the number of people around the world with these two ailments reached 339.4 million and 384.2 million in 2024, respectively. In addition, the Robert Koch Institute (RKI) calculated the net COPD incidences in Germany to be 5.9 million in 2025, exhibiting a 14.2% rise from 2018. On the other hand, the rising burden of comorbidities, such as air pollution, smoking, and aging, is amplifying this pool. This demography indicates the presence of sustainable demand for required medicines and hence propelling growth in the asthma and COPD drugs market.
The payers' pricing of available commodities in the asthma and COPD drugs market is witnessing significant inflation, which is overburdening patients with additional expenses. This can be displayed through the recent increases in key economic indicators. For instance, in 2024, the producer price index (PPI) for these formulations rose by 3.3% on account of increasing API costs and regulatory burdens, as per the U.S. Bureau of Labor Statistics. Simultaneously, this upward trajectory also flew down to the consumer price index (CPI) in the same category with a 4.2% annual hike. Furthermore, the premium pricing of branded drugs is pushing biopharma companies to cultivate more affordable biologic therapies, such as biosimilars.
